Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats
- 6 September 2024
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (2) , 388-400
Abstract
Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiological and neuroanatomical underpinnings remain elusive. In parallel, the unmet need for a better treatment of schizophrenia requires the development of novel therapeutic strategies. Cannabidiol (CBD), a major non-addictive phytocannabinoid has been linked to antipsychotic effects with unclear mechanistic basis. Therefore, this study aims to clarify the neurobiological substrate of repeated KET administration model and to evaluate CBD’s antipsychotic potential and neurobiological basis. CBD-treated male rats with and without prior repeated KET administration underwent behavioral analyses, followed by multilevel analysis of different brain areas including dopaminergic and glutamatergic activity, synaptic signaling, as well as electrophysiological recordings for the assessment of corticohippocampal and corticostriatal network activity. Repeated KET model is characterized by schizophrenia-like symptomatology and alterations in glutamatergic and dopaminergic activity mainly in the PFC and the dorsomedial striatum (DMS), through a bi-directional pattern. These observations are accompanied by glutamatergic/GABAergic deviations paralleled to impaired function of parvalbumin- and cholecystokinin-positive interneurons, indicative of excitation/inhibition (E/I) imbalance. Moreover, CBD counteracted the schizophrenia-like behavioral phenotype as well as reverted prefrontal abnormalities and ventral hippocampal E/I deficits, while partially modulated dorsostriatal dysregulations. This study adds novel insights to our understanding of the KET-induced schizophrenia-related brain pathology, as well as the CBD antipsychotic action through a region-specific set of modulations in the corticohippocampal and costicostrtiatal circuitry of KET-induced profile contributing to the development of novel therapeutic strategies focused on the ECS and E/I imbalance restoration.Keywords
Funding Information
- General Secretariat for Research and Innovation (1203, 02075, 02075, 04301, 02075, 02075, 02075, 02075, 04301, 04301, 04301, 02075, 04301)
- "la Caixa" Foundation (52410024, 52410024, 15493)
- "la Caixa" Foundation
- "la Caixa" Foundation
This publication has 116 references indexed in Scilit:
- Psychoactive properties of BNN27, a novel neurosteroid derivate, in male and female ratsPsychopharmacology, 2020
- Site of Ketamine Action on the NMDA Receptor2020
- Schizophrenia—An OverviewJAMA Psychiatry, 2020
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatmentWorld Psychiatry, 2020
- Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode PsychosisJAMA Psychiatry, 2019
- Nature of Glutamate Alterations in SchizophreniaJAMA Psychiatry, 2016
- Loss of Phenotype of Parvalbumin Interneurons in Rat Prefrontal Cortex Is Involved in Antidepressant- and Propsychotic-Like Behaviors Following Acute and Repeated Ketamine AdministrationMolecular Neurobiology, 2014
- Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in ratsPsychopharmacology, 2011
- Abnormal Frontostriatal Interactions in People With Prodromal Signs of PsychosisArchives of General Psychiatry, 2010
- Agonistic Properties of Cannabidiol at 5-HT1a ReceptorsNeurochemical Research, 2005